Ovarian reserve after uterine artery embolization in women with morbidly adherent placenta: A cohort study
- PMID: 30496259
- PMCID: PMC6264507
- DOI: 10.1371/journal.pone.0208139
Ovarian reserve after uterine artery embolization in women with morbidly adherent placenta: A cohort study
Abstract
Objective: To evaluate ovarian reserve in women after preservative cesarean delivery using uterine artery embolization due to morbidly adherent placenta.
Study design: A historical cohort study including all women admitted to a single tertiary care center, with morbidly adherent placenta that had preservative cesarean delivery with bilateral uterine artery embolization. Inclusion criteria included gestational age >24 weeks, singleton pregnancy and placenta increta / percreta. Exclusion criteria included maternal age > 43 years old and cesarean hysterectomy. Control group included women attending the infertility clinic due to male factor or single women conceiving via sperm donation, matched by age. Blood samples were collected on day 2-5 of menstruations for hormonal profile and Anti Mullarian Hormone (AMH) levels. Primary outcome was ovarian reserve evaluated by the levels of AMH.
Results: 59 women underwent preservative cesarean delivery using uterine artery embolization during the study period. 21 women met inclusion criteria (33.9%) and were matched controls (n = 40). Circulating levels of E2 and FSH did not differ significantly between the two groups (p = 0.665, p = 0.396, respectively). AMH was lower in the study group (median 0.8 IQR 0.44-1.80) compared to the controls (median 2.08 IQR 1.68-3.71) (p = 0.001). This finding was consistent in linear multivariate regression analysis where the group of cesarean delivery using bilateral artery embolization due to placenta accrete was significantly predictive for the levels of AMH (B = -1.308, p = 0.012).
Conclusion: Women post preservative cesarean delivery using uterine artery embolization due to placenta accrete have lower ovarian reserve compare to controls matched by age.
Conflict of interest statement
The authors have declared that no competing interests exist.
References
-
- Su HW, Yi YC, Tseng JJ, Chen WC, Chen YF, Kung HF, et al. Maternal outcome after conservative management of abnormally invasive placenta. Taiwan J Obstet Gynecol. 2017;56(3):353–7. 10.1016/j.tjog.2017.04.016 - DOI - PubMed
-
- Bauer ST, Bonanno C. Abnormal placentation. Semin Perinatol. 2009;33(2):88–96. 10.1053/j.semperi.2008.12.003 - DOI - PubMed
-
- Oyelese Y, Smulian JC. Placenta previa, placenta accreta, and vasa previa. Obstet Gynecol. 2006;107(4):927–41. 10.1097/01.AOG.0000207559.15715.98 - DOI - PubMed
-
- Eshkoli T, Weintraub AY, Sergienko R, Sheiner E. Placenta accreta: risk factors, perinatal outcomes, and consequences for subsequent births. Am J Obstet Gynecol. 2013;208(3):219.e1-7. - PubMed
-
- Eller AG, Porter TF, Soisson P, Silver RM. Optimal management strategies for placenta accreta. BJOG. 2009;116(5):648–54. 10.1111/j.1471-0528.2008.02037.x - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
